Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 641-647 , October 2008

Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study

  • Steven R. Goldsmith, MD

      Affiliations

    • Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationReprint requests: Steven R. Goldsmith, MD, Cardiology Division, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415.
    • ,
  • Uri Elkayam, MD

      Affiliations

    • University of Southern California, Los Angeles, California
    • ,
  • W. Herbert Haught, MD

      Affiliations

    • Huntsville Hospital, Huntsville, Alabama
    • ,
  • Abhijit Barve, MD, PhD

      Affiliations

    • Astellas Pharma US, Inc, Deerfield, Illinois
    • ,
  • Weizhong He, PhD

      Affiliations

    • Astellas Pharma US, Inc, Deerfield, Illinois

Received 19 December 2007 ,Revised 19 May 2008 ,Accepted 2 June 2008.

References 

  1. Congestive heart failure in the United States: a new epidemic. Data Fact Sheet. http://library.thinkquest.org/27533/Available at: facts.html Accessed August 2, 2007
  2. Felker GM, Adams KF, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145(Suppl 2):S18–S25
  3. Fonarow GC. ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21–S30
  4. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  5. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968
  6. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290–1295
  7. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99–104
  8. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10–38
  9. Gheorghiade M. The clinical effects of vasopressin receptor antagonists in heart failure. Cleve Clin J Med. 2006;73(Suppl 2):S24–S29
  10. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  11. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–1331
  12. Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol. 2004;19:254–263
  13. Cheng JW. Tezosentan in the management of decompensated heart failure. Cardiol Rev. 2005;13:28–34
  14. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR. et al, for the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–683
  15. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263–266
  16. Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med. 1982;72:49–52
  17. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385–1390
  18. Wong LL, Verbalis JG. Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am. 2002;31:121–140
  19. Goldsmith SR. Vasopressin antagonists in CHF: ready for clinical trials?. Cardiovasc Res. 2002;54:13–15
  20. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785–1791
  21. Tahara A, Tomura Y, Wada K-I, Kusayama T, Tsukada J, Takanashi M, et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997;282:301–308
  22. Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Tsukada J, et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999;376:239–246
  23. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  24. Burnier M, Fricker AF, Hayoz D, Nussberger J. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol. 1999;55:633–637
  25. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447–457
  26. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883–1891
  27. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005;95(Suppl):8B–13B

 This study was supported by Astellas Pharma US, Inc (formerly Yamanouchi Pharma America, Inc).

PII: S1071-9164(08)00178-4

doi: 10.1016/j.cardfail.2008.06.003

Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 641-647 , October 2008

Article Tools

* Image Usage & Resolution